The opioid crisis. Right to Try legislation. The first human trials of CRISPR-Cas9 gene editing technology. These are just a few of the many topics at the feet of the FDA this year.
Speaking at the BIO CEO & Investor Conference in New York on Tuesday, principal deputy commissioner Rachel Sherman, the FDA’s second in command to commissioner Scott Gottlieb, fired through a variety of issues affecting the agency both now and in the future.
Here are just a few tidbits from the chat, moderated by Biotechnology Industry Organization president and CEO Jim Greenwood.
Right to Try
A Republican-led push is… Read more »
UNDERWRITERS AND PARTNERS